The PancraGEN report includes:
Categorizes patients into four groups according to their risk of cancer:
|Low Risk Supports Surveillance
|Benign||Statistically Indolent (SI)
|97% probability of benign outcome at follow-up for up to nearly 8 years||97% probability of benign outcome at follow-up for up to nearly 8 years
|High Risk Supports Intervention
|Statistically Higher Risk (SHR)||Aggressive
|31x increased risk of cancer (HR=31, P<0.0001)||76x increased risk of cancer (HR=76, P<0.0001)
AccuCEA & Amylase results if generated and run by Interpace Diagnostics
(Any test information provided to Interpace Diagnostics by the submitting physician will not be included here, but incorporated into the Patient Profile section and referenced in the Comment section)
Diagnostic Category & Integrated Diagnostic Features
Provides a detailed description of the patient’s diagnostic category and risk of cancer including the specific features and information considered in determining the patient’s integrated diagnosis.
Summarizes clinical and molecular features used to determine diagnostic category predicting current and future biological behavior.